Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Sintilimab, Bevacizumab, and Chemotherapy in Resectable NSCLC
NCT04973293Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Oct 2022
- Primary completion
- Dec 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Open-label, single-arm trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Ruijin Hospital. Primary endpoint: Rate of grade 3 and higher grade treatment-related adverse events. Started Oct 2022; status: recruiting.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04973293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04973293.